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ABSTRACT 
 
Background: The HERC2 gene encodes a 527kDa E3 ubiquitin protein ligase that has key 
roles in cell cycle regulation, spindle formation during mitosis, mitochondrial functions and DNA 
damage responses. It has essential roles during embryonic development, particularly for 
neuronal and muscular functions. To date, missense mutations in HERC2 have been associated 
with an autosomal recessive neurodevelopmental disorder with some phenotypic similarities to 
Angelman syndrome, and a homozygous deletion spanning HERC2 and OCA2 causing a more 
severe neurodevelopmental phenotype. Methods and results: We ascertained a 
consanguineous family with a presumed autosomal recessive severe neurodevelopmental 
disorder that leads to paediatric lethality. In affected individuals, we identified a homozygous 
HERC2 frameshift variant that results in a premature stop codon and complete loss of HERC2 
protein. Functional characterization of this variant in fibroblasts, from one living affected 
individual, revealed impaired mitochondrial network and function as well as disrupted levels of 
known interacting proteins such as XPA. 
Conclusion: This study extends the genotype-phenotype correlation for HERC2 variants to 
include a distinct lethal neurodevelopmental disorder, highlighting the importance of further 
characterization for HERC2-related disorders. 
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INTRODUCTION  
Inherited neurodevelopmental disorders are a group of conditions with extensive genetic 
heterogeneity that present in the perinatal and paediatric age ranges and arise from a disruption 
in the development of the central nervous system. Common phenotypic characteristics shared 
by the majority of neurodevelopmental disorders include developmental delay, impaired motor 
function and intellectual disability. Structural brain abnormalities such as microcephaly and gyral 
defects are also observed in neurodevelopmental conditions. These phenotypes have 
considerable overlap and variability, and can be indistinguishable on clinical grounds. A specific 
genetic diagnosis for an inherited neurodevelopmental disorders therefore enables accurate 
genetic counselling and better clinical management of patients and their families. 
 
The HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2) gene encodes a 
527kDa E3 ubiquitin protein ligase of multiple structural domains, including the cell cycle 
regulator RCC1 and C-terminal HECT domains that are shared by various E3 ubiquitin protein 
ligases(1). The exact functions of HERC2 are still incompletely understood, but recent evidence 
suggests HERC2 targets key DNA damage response proteins, such as XPA and BRCA1, for 
degradation through the ubiquitin-proteasome system(2, 3). XPA is a DNA damage recognition 
protein that plays a key role in the nucleotide excision repair (NER) mechanism, and its correct 
turnover by HERC2 can significantly affect the circadian oscillation of NER activity, particularly 
in the brain(4). HERC2 also interacts with another E3 ubiquitin protein ligase, UBE3A, which 
when mutated has been shown to cause Angelman syndrome(5). Other important protein-
protein interactions of HERC2 include proteins that are involved in cell cycle regulation, spindle 
formation during mitosis(6) and mitochondrial bioenergetics (7). 
 
Two pathogenic missense variants in HERC2 have been reported in individuals with 
developmental syndromes. Twenty-two individuals from three different Amish/Mennonite 
families homozygous for p.Pro594Leu were affected with autosomal recessive Mental 
Retardation type 38 (MIM 615516), described as an autism spectrum disorder phenotype with 
some similarities to Angelman syndrome (8, 9). Common features included speech and 
language delay, gross motor delay, autistic features, seizures and childhood hypotonia. Two 
individuals have been reported with homozygous p.Arg1542His variants, with similar clinical 
features (7). Furthermore, a study has reported a single patient, presenting with severe 
developmental abnormalities and ocular albinism, who carries a homozygous deletion of the 
contiguous genes HERC2 and OCA2 resulting in a fusion protein(10). 
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In this study, we describe a family presenting with a non-specific severe neurodevelopmental 
disorder characterized by profound developmental delay, blindness and perinatal mortality. We 
identified a homozygous frameshift variant in HERC2 as the causative mutation in affected 
individuals resulting in a lack of HERC2 protein. To our knowledge, this is the first report of a 
specific HERC2 null allele causing a more severe neurodevelopmental disorder that does not 
resemble Angelman syndrome. This expands the genotype-phenotype correlations for HERC2-
related disorders. 
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MATERIALS AND METHODS 
 
Patients 
Members of the family were recruited following informed consent under ethical approval for 
molecular genetics research studies from South Yorkshire Research Ethics Committee (REC 
ref. no. 11/H1310/1). The study adhered to the Tenets outlined in the Declaration of Helsinki. 
Genomic DNA was obtained from blood samples using a standard salt precipitation protocol. 
Skin punch biopsies (4-6mm) were obtained under local anesthesia from a single affected child 
of the family (II:6).  
 
Whole Exome Sequencing  
Whole exome sequencing (WES) was performed on genomic DNA from the three affected 
siblings alongside one unaffected sibling (marked with ‘*’ in Figure 1A) from the family. 
Genomic DNA was diluted to 25ng/μl and processed using the Agilent SureSelect QXT Target 
Enrichment kit according to manufacturer’s protocol (Agilent Technologies, CA, USA). DNA 
libraries were pooled and sequenced on an Illumina HiSeq 3000 using a 150 bp paired-end 
protocol. 
 
Bioinformatics Analysis 
The Burrows-Wheeler Aligner (BWA) was used to align .fastq files to the human reference 
genome (GRCh37). The resulting bam file was further processed using Picard tools and the 
Genome Analysis Toolkit (GATK), according to best practice guidelines, to mark possible PCR 
duplicates and check for accurate alignment around indels. Variants were called using 
HaplotypeCaller (GATK) and filtered against NCBI’s dbSNP146, excluding any variants with a 
minor allele frequency (MAF) ≥1%. Variants were also excluded if present with a MAF ≥1% in 
the Exome Aggregation Consortium (ExAC; v0.3.1) and Genome Aggregation Consortium 
(gnomAD; r2.0.2) databases. All remaining variants that segregated in an autosomal recessive 
mode of inheritance were annotated using Ensembl’s Variant Effect Predictor (VEP) to predict 
functional consequences. Variants with a Combined Annotation Dependent Depletion (CADD) 
score of ≤15 were also excluded. Homozygosity mapping was performed using vcf files prior to 
filtering on dbSNP to identify homozygous regions shared by the affected individuals of the 
family using AgileMultiIdeogram (http://dna.leeds.ac.uk/agile/AgileMultiIdeogram/).  
 
PCR and Sanger Sequencing  
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Segregation of the HERC2 variant in the family was determined by PCR and Sanger 
sequencing using primers flanking exon 90 (Forward: 5’-AGATGCACTTGAGGCTGACC, 
Reverse: 5’-TGGAGCCAAATCCATTACTTT). PCR was performed using HotShot Master Mix 
protocol (Clent Life Sciences) and Sanger sequencing was carried out using BigDye Terminator 
v3.1 kit (Life Technologies, CA, USA) according to the manufacturer’s protocol. Sequencing was 
resolved on an ABI3130xl Sequencer (Life Technologies) and the electropherograms were 
analysed using 4Peaks software. 
 
Cell Culture 
Primary lines of human dermal fibroblasts (HDF) were derived from skin biopsies of healthy and 
affected individual II:6 (Figure 1A). Primary HDF were cultured in Dulbecco’s Modified Eagle 
Medium: Nutrient Mixture F-12 (DMEM/F12) supplemented with 10% fetal calf serum at 37¡C/ 
5%CO2. 
 
Western Blotting  
Whole-cell protein extracts (WCE) were obtained from primary HDFs. Total soluble protein was 
collected using NP40-lysis buffer (50mM Tris-HCl pH 8.0, 150mM NaCl, 1% [v/v] NP-40, 1X 
protease/phosphatase inhibitors) and proteins were then separated on 7% NuPAGE Tris-
acetate gels for higher molecular weight proteins. Proteins were transferred on to a methanol 
activated PVDF membrane for 5 hours at 40mA at 4¡C. Immunoblot analysis was performed 
using 1:1000 dilution of rabbit anti-HERC2 antibody (Bethyl Laboratories, Inc). Lower molecular 
weight proteins were separated on 4-12% NuPAGE Bis-Tris SDS-PAGE gels and transferred 
onto PVDF membranes using 90 min transfer at 30mA. Immunoblot analysis was performed 
using 1:1000 dilution of rabbit anti-PCM1 antibody (Proteintech Group), 1:500 of rabbit anti-XPA 
(a kind gift from Prof Majlinda Lako) and 1:1000 of rabbit anti-CEP170 (a kind gift from Prof 
Marius Ueffing). Primary antibodies were detected using a species appropriate HRP-conjugated 
antibody (Dako) at a 1:5000 dilution. Detection of HRP was achieved using the SuperSignal™ 
West Femto immunoblot detection system (ThermoFisher Scientific). 
 
Immunofluorescence and Confocal Microscopy 
Cells were seeded in 24-well plates on glass coverslips and 24 hours later fixed in ice-cold 
methanol for 5 minutes at -20¡C. Fixed coverslips were blocked in 1% [w/v] non-fat milk solution 
and stained with mouse anti-MTCO2 (Abcam) at a final dilution of 1:1000. Appropriate 
secondary antibodies (Alexa Fluor ®, ThermoFisher Scientific) and DAPI were used at final 
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dilutions of 1:1000. Confocal images were acquired with a Nikon A1R Confocal Microscope 
using NIS Elements software. Images were processed using FIJI software.  
 
Seahorse Metabolism Assays 
Seahorse MitoStress and Glycolysis Stress tests were performed in three biological replicates 
on 96-well plates according to manufacturer’s instructions (Agilent Technologies). Primary 
fibroblasts obtained from a single affected child (II:6) and an age-matched healthy control (both 
passage number = 3) were seeded in the Seahorse XF Cell Culture Microplate at a seeding 
density of 15,000 cells per well. For the MitoStress assay the following toxins were used: 1.0 μM 
oligomycin, 2.0 μM FCCP and 0.5 μM rotenone/antimycin A at. For the Glycolysis Stress assay 
the following toxins and substrates were used: 10.0 mM glucose, 1.0μM oligomycin and 50.0 
mM 2-deoxyglucose (2-DG). At the end of each assay, the differences between the cell 
numbers in each well were normalised by histological staining with 1.0% [w/v] Crystal Violet, 
solubilisation with methanol and standard colorimetric quantification. We used Agilent Seahorse 
Wave Desktop software for data analysis.  
 
Statistical Analysis 
Normal distribution of data (Seahorse MitoStress and Glycolysis Stress tests, quantification of 
western blots) was confirmed using the Kolmogorov-Smirnov test (GraphPad Software). 
Pairwise comparisons were analyzed by Student's two-tailed t-test using Prism 7 (GraphPad 
Software). Results reported are from at least three independent biological replicates. Error bars 
on graphs represent standard error of the mean (s.e.m.) 
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RESULTS 
 
Clinical Ascertainment 
Three Libyan siblings with profound developmental delay were recruited to the study (Figure 
1A). Their parents were distantly related (3rd cousins). There was no known family history of 
similar developmental delay. None of the children had developed verbal or non-verbal 
communication skills, speech comprehension, head control or purposeful hand movements. 
None achieved ambulation. The children had structurally normal eyes but could not fix or follow, 
all were thought to be blind. All three children had choreiform movements and orofacial 
dyskinesias, were hypotonic and hypermobile. The affected boy had a horseshoe kidney and 
bilateral gross hydronephrosis with reduced renal cortex. None of the children had any specific 
facial dysmorphism, limb or cutaneous abnormalities. A urine metabolic screen for affected child 
II:3 did not reveal any specific findings, showing normal urine organic acid, acyl carnitine and 
amino acid levels. Serum lactate levels were normal (1.6 mmol/L) with no evidence of metabolic 
acidosis. All were gastrostomy fed. The younger two both suffered recurrent urinary tract 
infections. The two female children suffered recurrent seizures. II:3 died at the age of 7 years 
following a seizure, and II:4 died at 4 years due to respiratory failure.  
 
All the affected siblings had MRI brain imaging. All had hypoplasia of the brain stem, and corpus 
callosum. All had signs of cortical migration abnormalities: II:3 with bilateral grey matter 
heterotopia, II5 with bifrontal polymicrogyria and potential cerebellar polymicrogyria, and II:6 
with generalized polymicrogyria including in the cerebellum (Figure 1B). A summary of the 
clinical features observed in these affected individuals, as well as clinical features of all 
individuals reported previously with HERC2 pathogenic mutations, are listed in Table 1. 
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Publication 
and 
pedigree 
 Individual  Gender Age seen 
(years) 
Speech Walked 
(years) 
Intellectual 
disability 
Childhood 
hypotonia 
Seizures Neuroimaging Blindness Genotype 
(NM_004667.5) 
this report II:3 F 6 (died 7) N N ++++ Y Y CMD, ACC Y c.13767_13770delTGAA 
p.(Asn4589LysfsTer4598) II:5 M 1.5 (died 4) N N ++++ Y N CMD, ACC Y 
II:6 F 3.5 N N ++++ Y Y CMD, ACC Y 
Harlalka et al. 
2013: 1A(9) 
VIII:7 F 39 100 
words 
4.3 ++ Y N Nor N  
 
 
 
 
c.1781C>T, 
p.(Pro594Leu);  
VIII:8 M 35 <30 
Words 
4.3 ++/+++ Y N NK N 
IX:1 F 24 SS 4 ++ Y N NK N 
IX:6 M 17 SS 4 ++ Y Y NK N 
IX:7 F 19 SS 4 ++ Y N Nor N 
X:1 F 13.6 <30 
words 
4 ++ Y N Nor N 
X:2 F 12.6 10 
words 
4 ++ Y N NK N 
X:4 F 5.1 N N ++/+++ Y N ACC N 
X:5 F 6.7 SS 5 ++ Y N NK N 
XI:2 M 7.8 Limited 3.5 + Y N NK N 
XI:3 M 5.1 20 
words 
N ++ Y Y ACC N 
Harlalka et al. 
2013: 1B(9) 
IX:8 M 17.8 SS 4.5 +/++ NK Y ACC N  
c.1781C>T, 
p.(Pro594Leu) 
IX:10 M 16.8 SS 4 +/++ NK N NK N 
IX:1 F 0.97 N N ++ Y Y NK N 
IX:2 F 2.7 <10 
words 
N +/++ Y N NK N 
Puffenberger 
et al. 2012 
(8) 
Michigan 
sibship P1 
NK 32 NKa NKb +/++/+++c Y N NK N  
 
c.1781C>T, 
p.(Pro594Leu) 
Michigan 
sibship P2 
NK 25 NKa NKb +/++/+++c Y N NK N 
Michigan 
sibship P3 
NK 31 NKa NKb +/++/+++c N N NK N 
Wisconsin 
sibship P1 
F 7 NKa NKb +/++/+++c N Y NK N  
c.1781C>T, 
p.(Pro594Leu) Wisconsin 
sibship P2 
F 2 NKa NKb +/++/+++c N Y NK N 
Puffernberger 
et al. 2012 
(8)/ Abraham 
et al. 2019 
(7) 
Puffenberger 
Ohio sibship 
P1/Abraham 
#1 
F Puffenberger: 
40 
Abrahams: 
47 
NKa NKb +/++/+++c N N NKd N  
c.1781C>T, 
p.(Pro594Leu) 
Puffernberger 
Ohio sibship 
P2/Abraham 
#2 
M Puffenberger: 
37 
Abrahams: 
43 
NKa NKb +/++/+++c N N NKd N 
Abraham et 
al. 2019 (7) 
#3 M 23 Few 
words 
Nor ++ N N NK NK c.4625G>A, 
p.Arg1542His 
#4 F 11 10 
words at 
Nor + N Y N N 
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2 years, 
SS at 3 
years 
Morice-
Picard et al. 
2017 (10) 
Proband M 0, died 2 
years 
NK NK NK Y NK ACC, CMD, 
megacisterna 
magna 
NK (moderate 
retinal 
hypopigmentation) 
chr15: g. 
28143765_28429460 del 
including OCA2 and 
HERC2 
 Proportion 
with feature 
(where 
known) 
Delayed 
speech: 
20/20  
Delayed 
walking: 
18/20 
Intellectual 
disability: 
27/27 
Childhood 
hypotonia: 
19/26  
Seizures: 
9/27  
Abnormal 
neuroimaging: 
7/11 
Blindness: 3/26  
 
Table 1: Summary of clinical features for affected individuals with HERC2 mutations 
 
Abbreviations and symbols: abn = abnormal, ACC = absent corpus callosum, CMD = cortical migration defect, F = female, M = male, NK = not known, N = no, nor = normal, SS = short 
sentences, Y = yes , + = mild, ++ = moderate, +++ = severe, ++++ = profound  
NKa: details of individual cases not known. Most had words by two years 
NKb: details of individual cases not known. Walked at average of 3.5 years (range 2.25 - 5 years)          
+c: details of individual cases not known. Range mild - moderate/severe      
NKd: details of individual cases not known. One sibling with normal MRI and one with mild cerebral atrophy
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Whole Exome Sequencing  
Genomic DNA samples from the three affected individuals and an unaffected sibling were taken 
forward for WES library preparation using the Illumina QXT protocol, and sequencing was 
performed on an Illumina HiSeq 3000. Prior to data analysis, .fastq files and subsequent .bam 
files were assessed for sequence quality. An in-house bioinformatics pipeline was used for data 
analysis, assuming a recessive mode of inheritance, to filter out variants that were not 
compatible with Mendelian segregation based on the family’s pedigree. 
 
To assist with variant filtration, autozygosity mapping was performed using the .vcf files of each 
sibling prior to SNP filtering. This revealed five regions of autozygosity shared between the 
three affected siblings but not the unaffected sibling. Using the described criteria, only a single 
homozygous frameshift variant c.13767_13770delTGAA in HERC2 remained, which was 
present within the largest shared homozygous region (Figure 1C). This frameshift is predicted 
to affect the protein from residue Asn4589, resulting in a premature termination codon 
p.(Asn4589LysfsTer4598) The variant has a CADD (v1.3) score of 34 and is absent from 
dbSNP151 and gnomAD (v2.1.1). Sanger sequencing confirmed the presence of the variant and 
appropriate segregation in all available family members (Figure 1D). 
 
Effect of the HERC2 p.Asn4589LysfsTer4598 null allele on mitochondrial functions 
To investigate the impact of the truncating mutation on the HERC2 protein, patient dermal 
fibroblasts were obtained from an affected individual (II:6) and soluble cellular protein extracted. 
Immunologically-detectable HERC2 was absent in the insoluble cellular fraction after extraction 
(data not shown). A western blot against HERC2 revealed complete loss of full-length HERC2 
protein as a result of the frameshift deletion (Figure 2A) compared to control HDFs. Based on 
this result, the patient fibroblasts were proven to carry a homozygous HERC2 null allele, and 
were subsequently used to further characterize the impact of the mutation on cellular 
phenotypes and protein interactions. 
 
The phenotype of severe delay, seizures, and profound visual loss, muscle weakness and 
hypotonia observed in affected family members suggested that loss of HERC2 may affect 
mitochondrial function. Recent evidence also suggests that HERC2 mediates DNA repair and 
cell cycle regulation, critical to cellular homeostasis in the maintenance of mitochondrial 
dynamics and function(11-13). In addition, previous proteomic analysis on lymphoblastoid cell 
lines derived from patients with HERC2 homozygous mutations p.Pro594Leu and p.Arg1542His 
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compared to control cell lines, revealed significant up-regulation of mitochondrial dysfunction 
pathways, especially mitochondrial bioenergetics, suggesting a potential role for HERC2 in 
mitochondrial biology(7). Mitochondrial morphology was therefore assessed in control and 
patient HDFs by immunofluorescence microscopy. We observed striking mitochondrial 
fragmentation in the patient fibroblasts compared to the control (Figure 2B). 
 
To further elucidate the effect of HERC2 loss on mitochondrial function, the oxidative 
phosphorylation pathway and glycolytic pathway of energy production were tested using a 
Seahorse XFe96 Extracellular Flux Analyzer. Control and patient HDFs were challenged with 
inhibitors that affect different stages of each pathway and the oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) were measured before and after each inhibitor 
treatment, giving overall traces for the MitoStress and Glycolysis Stress assays, respectively 
(Figures 2C, 2E). Measurements of oxidative phosphorylation function were determined from 
the traces in order to determine ATP production, basal and maximal respiration, proton leak and 
spare respiratory capacity (Figure 2D). Basal respiration, ATP production, proton leak and 
coupling efficiency were significantly disrupted in mutant HERC2 cells compared to normal 
controls. Similarly, glycolytic pathway and glycolytic potential measurements showed that 
HERC2 mutant fibroblasts from affected individual II:6 had a significantly increased non-
glycolytic acidification level compared to the normal control fibroblasts (Figure 2F). This 
suggested a source of acidification separate to the glycolysis pathway since the levels of 
glycolysis, glycolytic capacity and glycolytic reserve were indistinguishable between the two cell-
lines. 
 
Effect of the HERC2 p.Asn4589LysfsTer4598 null allele on protein-protein interactions 
The impact of complete loss of HERC2 on potential interacting and target proteins was also 
investigated. Interacting proteins were chosen from either UniProt interaction data or manual 
collation of the primary literature(4, 6). Since HERC2 is an E3 ubiquitin-ligase protein, we 
hypothesized that HERC2 loss would cause an increase in protein levels of XPA as it is 
considered to be a potential substrate tagged for degradation. HERC2 has also been reported 
to be a modulator of centrosome architecture (11) and is implicated in cell cycle regulation and 
mitosis. Both CEP170 and PCM1 are centrosomal proteins that are annotated as both hits and 
baits in reciprocal affinity capture-MS interaction studies of HERC2 (see BioGRID3.5 result 
summary https://thebiogrid.org/114438), and that both affect downstream cell cycle-dependent 
processes(6, 14, 15). CEP170 and PCM1 also interact with the same RCC1 domain as UBE3A, 
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potentially sharing a cellular mechanism that, when disrupted, causes Angelman-like or more 
severe developmental phenotypes(16). Soluble protein was extracted from control and patient 
HDFs and the protein levels of XPA, CEP170 and PCM1 were quantified by western blot. This 
revealed significant changes in the protein levels of all three interacting proteins (Figure 3). As 
predicted, intracellular XPA levels were significantly increased in affected HDFs compared to 
normal healthy control HDFs. Conversely, intracellular levels of CEP170 and PCM1 were 
significantly decreased in affected HDFs compared to the controls. 
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DISCUSSION 
Loss of HERC2 is likely to affect many cellular processes, specifically cell cycle regulation and 
DNA repair mechanisms, resulting in cellular stress and defective cellular homeostasis as a 
downstream consequence(11, 12). Unbalanced homeostasis can be critical in mitochondrial 
dynamics and function. This was confirmed by the observation of striking fragmentation of the 
mitochondrial network observed in mutant fibroblasts compared to normal controls, which is a 
key feature of mitochondrial stress. This observation was further examined by live cell metabolic 
assays, evaluating both the oxidative phosphorylation and the glycolysis pathways. 
Measurements from real-time traces revealed significantly reduced basal respiration levels and 
ATP production in the HERC2-mutated cells from affected individual II:6, indicative that the 
mutant cells have switched their energy production to other less efficient means than oxidative 
phosphorylation(17). One of the reasons for doing so could be a defect in ionic homeostasis due 
to altered proton leak in the mitochondria, as observed following treatment with the decoupler 
FCCP, leading to reduced proton-motive force and aerobic ATP production. 
 
For the Glycolysis Stress assay, the level of glycose-to-pyruvate conversion was very similar 
between normal control and affected HDFs. In addition, there was no significant difference 
between the glycolytic capacity and glycolytic reserve, indicating that under normal conditions 
the level of glycolysis in both cell types was the same and, when forced, both can reach 
maximum glycolysis. A significant increase was observed, however, in non-glycolytic 
acidification levels in mutant fibroblasts from the affected individual II:6 compared to controls. 
This observation implies a source of acidification other than the glycolysis pathway, potentially 
arising from the conversion of pyruvate to lactate in order to maintain energy requirements for 
HERC2-mutated cells(18). The observation of defective mitochondrial bioenergetics, specifically 
the oxidative phosphorylation pathway, supports the findings of Abraham et al. 2019 that 
suggest HERC2 has a key role in mitochondrial function (7).  
 
Due to the multiple functions of HERC2, principally as an E3 ubiquitin protein ligase, the 
complete loss of the protein is expected to have an impact on interactants and substrates. To 
test this hypothesis, we examined the protein levels of various known substrates in HDFs from 
affected individual II:6. Levels of XPA, a known HERC2 interactant(2), were increased in 
HERC2-mutated cells compared to the controls, supporting the hypothesis that XPA is a 
substrate tagged for degradation by HERC2 and that is consistent with the findings in a previous 
study(10). Loss of HERC2 therefore results in incorrect turnover of XPA(2), which could critically 
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affect downstream DNA repair mechanisms or promote a pathogenic outcome due to 
aggregation of protein complexes. 
 
Roles for HERC2 have also been described in mitosis, spindle formation and cell cycle 
regulation by interacting with centrosomal and cell cycle regulating proteins or ubiquitinating 
these proteins for specific signaling purposes(6, 19, 20), including PCM1 and CEP170. PCM1 
(pericentriolar material 1) is a component of centriolar satellites, and essential for centrosome 
assembly and function by correctly anchoring microtubules to the centrosome(21). PCM1 is also 
involved in regulating primary cilia disassembly before entering mitosis(12). CEP170 
(centrosomal protein 170kDa) is another component of the centrosome, but is specifically 
localized to the mother centriole at the subdistal appendages as well as in spindle formation and 
maintenance of microtubular organization(22). Both of these proteins are key regulators of cell-
cycle dependent events, and are both significantly reduced in patient fibroblasts suggesting a 
potential systemic defect in cell cycle regulation and cell division. These observations provide a 
potential explanation for the severe neurodevelopmental phenotypes observed in these 
patients.  
 
To date, only two pathogenic HERC2 missense variants have previously been reported 
(p.Pro594Leu and p.Arg1542His). Twenty-two individuals homozygous for p.Pro594Leu have 
been reported with what is described as an autism spectrum disorder that has phenotypic 
overlap with Angelman syndrome (8). All reported cases had speech and language delay where 
data was available (15/15), walking delay (22/22) and intellectual disability (22/22) varying from 
mild to severe, but with the majority being mild/moderate (7-9). Childhood hypotonia was 
reported in 15/20 with the p.Pro594Leu missense mutation. Two individuals homozygous for 
p.Arg1542His have also been reported, affected with similar delays in speech and language 
development and intellectual disability to affected individuals with p.Pro594Leu, but without the 
walking delay or childhood hypotonia(7). Seizures are not a consistent feature, reported in 6/22 
of the p.Pro594Leu cases and 1/2 of the p.Arg1542His cases. What is clear is that the cases we 
describe in the present report have a much more profound developmental phenotype to those 
previously reported with missense mutations. All the siblings in the present report have profound 
intellectual disability, no verbal or non-verbal communication skills, and no head control or 
purposeful movements. In addition, all affected individuals were blind, had involuntary 
choreiform movements and signs of cortical migration defects on neuroimaging not previously 
observed in other HERC2-mutated cases. Two out of three had seizures, and the two elder of 
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the three siblings had passed away at the time of ascertainment, aged 4 and 7 years. None of 
the previously reported affected individuals carrying missense mutations have died, with most 
being much older than the siblings described in the present report. 
 
A homozygous 286kb deletion that spans HERC2 and OCA2 has also been reported, in which a 
much more severe form of developmental delay and lethality was described (10). This is the 
only other report of an ocular phenotype in a HERC2-mutated individual, comprising moderate 
retinal hypopigmentation. However, this is consistent with deletion of the OCA2 gene, mutations 
in which are known to cause non-syndromic oculocutaneous albinism type 2 (MIM 203200). The 
deletion resulted in a HERC2-OCA2 fusion protein and complete loss of both HERC2 and 
OCA2. The complete loss of a large and important E3 ligase will have a detrimental effect on 
diverse cellular processes, including DNA damage repair and cell cycle regulation, which is also 
supported by the observation that the Herc2 homozygous null mouse is embryonically lethal 
(20).  
 
In summary, we have identified a family with a severe neurodevelopmental disorder due to 
complete loss of HERC2 and show that this has a significant impact on mitochondrial 
biogenesis and function, in addition to effects on the levels of known substrate proteins. This 
work establishes, for the first time, a clear genotype-phenotype correlation for the complete loss 
of HERC2. We suggest that HERC2 should be included in gene panels for non-specific severe 
neurodevelopmental disorders, in order to improve the sensitivity of diagnostic testing for 
patients with developmental delay but without a molecular diagnosis. This is important for the 
future stratification and management of inherited disorders with non-syndromic, profound 
developmental delay because, without a molecular diagnosis, these conditions are often 
clinically indistinguishable. 
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FIGURE LEGENDS 
 
Figure 1: Identification and segregation of HERC2 mutation  
(A) Pedigree of the Libyan family outlining two generations. DNA samples from individuals 
marked with an asterisks (*) were processes using WES. (B) MRI scans from individual II:5 at 3 
months of age. Axial T2-weighted image (left panel) showing reduced cerebral volume. The 
cortex is thickened bifrontally with loss of the grey/white matter interface and numerous 
interdigigtations indicative of polymicrogyria. Myelination is delayed with no evidence of 
myelination in the anterior limb of the internal capsule on either side, which is expected to be 
visible at this age. Corpus callosum agenesis is apparent and Sylvian fissures are slightly 
prominent. Coronal T2-weighted scan (middle) indicate cerebellar hypoplasia. Multiple small 
cerebellar folia and cerebellar polymicrogyria are apparent. Midline sagittal T2-weighted scan 
(right) show considerable evidence of cerebellar, brain stem, pontine and medullary hypoplasia. 
Cerebral polymicrogyria and agenesis of the corpus callosum are also apparent. (C) 
Homozygosity mapping performed on the samples processes by WES, using Agile 
MutliIdeogram tool. Regions highlighted on the ideogram represent homozygous genomic 
intervals shared by the affected individuals only. Specific coordinates are presented on the 
table. (D) Variant confirmation using Sanger sequencing. Top electropherogram represents 
wildtype control DNA and the box marks the four nucleotides that are deleted in the patients. 
Middle electropherogram is from parental DNA, with the line highlighting the breakpoint of the 
deletion. Heterozygous state of parental DNA shown here by the mismatch trace after the 
deletion point. Bottom panel is from affected individuals outlining the homozygous deletion and 
frameshift after the deletion point.  
 
Figure 2: Loss of HERC2 protein and impact on mitochondrial function  
(A) Western blot confirming loss of HERC2 protein. Protein extracted from wildtype and HERC2 
mutant fibroblasts from affected individual II:6. (B) Immunofluorescence using DAPI and 
MTCO2 antibody for mitochondrial imaging of wildtype and HERC2 mutant fibroblasts 
(magnification x100). (C) Mitostress test using Seahorse XFe96 Analyzer. Real-time readings of 
OCR (pmol/min) are illustrated. (D) Key aspects of mitochondrial function are calculated using 
OCR values. Statistical tests were performed by a two-tailed Student t-test (n=3; ns; not 
significant, * p <0.05, *** p <0.001) and error bars indicate s.e.m.. (E) Glycolysis stress test 
using Seahorse XFe96 Analyzer. Real-time readings of the ECAR (mpH/min) are illustrated. (F) 
Key aspects of glycolysis are calculated using ECAR values. Statistical tests were performed by 
a two-tailed Student t-test (n=3; ns; not significant, *** p <0.001) and error bars indicate s.e.m.. 
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Figure 3: Loss of HERC2 affects other interacting partners 
(A) Representation of protein levels on western blot membranes for the interacting proteins 
PCM1, CEP170 and XPA compared to loading control β-actin. Western blots include all three 
biological replicated of each experiment. (B) Bar graphs quantitating the results from all three 
biological replicates normalised to β-actin. All statistical tests were performed by a two-tailed 
Student t-test (n=3; ns, not significant; * p<0.05; ***p<0.001). Error bars indicate s.e.m.  
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